Healthcare / Medical DevicesSES
$0.08
-0.00 (-4.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-2.6M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$41M
P/E
N/A
•EV/EBITDA
10.0x
↓ROE
-1.8%
↓Gross Margin
51.2%
↑Debt/Equity
0.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-3.5%
FCF CAGR
—
FCF margin
-7.6%
FCF / Net income
5.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $102.4M · net income $-1.4M · FCF $-7.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $102.4M | $102.4M | $129.2M | $130.8M | $113.9M |
| Net Income | $-1.4M | $-1.4M | $4.2M | $8.8M | $10.4M |
| EBITDA | $6.9M | $6.9M | $13.2M | $17.9M | $19.0M |
| EPS | — | — | 0.01 | 0.02 | 0.02 |
| Gross Margin | 51.2% | 51.2% | 51.2% | 52.0% | — |
| Operating Margin | -4.8% | -4.8% | 3.1% | 4.6% | — |
| Net Margin | -1.3% | -1.3% | 3.3% | 6.8% | 9.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.44 | 0.44 | 0.22 | 0.36 | 0.27 |
| Current Ratio | 1.37 | 1.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.8M | $-7.8M | $12.5M | $-2.6M | $3.8M |
| Returns | |||||
| ROE | -1.8% | -1.8% | 5.4% | 11.3% | 14.5% |
| Valuation | |||||
| P/E | — | — | 16.83 | 11.47 | 9.65 |
| EV/EBITDA | 9.96 | 9.96 | 6.09 | 6.71 | 5.69 |
| P/B | 0.56 | 0.56 | 0.91 | 1.29 | 1.38 |
| Growth & Yield | |||||
| Revenue Growth | -20.8% | -20.8% | -1.2% | 14.8% | — |
| EPS Growth | — | — | -51.8% | -15.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → n/d
Residual
+3.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.